Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
2024年度关联方占用资金情况专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项报告" (special report) concerning non-operating fund occupation and other related party fund transactions for the year 2024. It includes detailed financial data about fund balances, transactions, and related party relationships, and it references an audit report issued on April 22, 2025. The document is not a full annual report but a specific audit-related report focusing on a particular financial aspect (non-operating fund occupation and related party transactions). It is not a general financial statement or earnings release but a specialized audit report. Given the nature of the document as a standalone audit-related report with detailed financial data and audit opinion references, it fits best under the category Audit Report / Information (AR). The document length is 2045 characters, which is short but contains substantive financial data and audit commentary, so it is not merely an announcement or certification. Therefore, the classification is AR with high confidence. FY 2024
2025-04-23 Chinese
关于选举公司监事会主席的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of the chairman of the supervisory board (监事会主席) of the company. It includes details about the election decision, the chairman's resume, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no discussion of management changes at the board or executive level, and no reference to shareholder votes or dividends. The document is a formal announcement of a governance-related event but specifically about the supervisory board chairman election, which is a management/board-related announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report or a regulatory filing but a specific announcement about a board position election.
2025-04-23 Chinese
2024年度募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Assurance Report) on the "募集资金年度存放与使用情况" (Annual Report on the Deposit and Use of Raised Funds) for the year 2024 by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes detailed information about the amount of funds raised, their deposit, usage, management, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is prepared according to specific regulatory guidelines for the management and use of raised funds by listed companies. It contains detailed financial data and analysis about the raised funds usage, project progress, and compliance, and is signed by a registered CPA firm. This is a specialized audit/assurance report focusing on the raised funds usage, not a full annual report or earnings release. It is not a mere announcement or certification but a substantive standalone audit/assurance report on a specific financial aspect. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2024
2025-04-23 Chinese
关于召开2024年年度股东大会通知公告
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on (including the 2024 annual report, board reports, financial statements, profit distribution, auditor reappointment, and remuneration plans), registration details, and attachments such as proxy forms and registration forms. The document does not contain the actual annual report or financial statements but rather serves as a formal notification to shareholders about the AGM and the matters to be discussed and voted upon. The presence of detailed voting instructions and meeting logistics confirms this is an AGM Information document, not the report itself or voting results.
2025-04-23 Chinese
董事会对独董独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory guidelines about independent directors and confirms compliance with independence requirements. There is no financial data, no report publication, no voting results, or other types of filings such as annual reports or earnings releases. This is a governance-related disclosure about board members' independence, which fits best under Governance Information (CGR). The document length is short and focused solely on governance compliance.
2025-04-23 Chinese
2024年度独立董事述职报告 （邵春阳）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2024 by an independent director of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the director's duties, attendance at board and committee meetings, communication with auditors, supervision of financial reporting, and governance activities during the year. It references compliance with company law, securities law, and stock exchange rules, and discusses oversight of financial reports and internal controls. The document is a detailed report on the independent director's activities and governance role rather than a general annual report or financial statement. It is not a simple announcement or certification but a substantive governance-related report. This fits best under the category of Board/Management Information (MANG), which includes announcements of changes or reports related to board members and senior management activities. The document is 4766 characters, which is substantive enough to be a full report rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2025-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.